Candel Therapeutics files Form 3 for Chief Commercial Officer Mark E. Sims

Candel Therapeutics filed a Form 3 naming Mark E. Sims as chief commercial officer in an initial statement of beneficial ownership dated July 6, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002139479-26-000003), on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Candel Therapeutics filed a Form 3 with the SEC, reporting that Mark E. Sims was named Chief Commercial Officer. The initial statement of beneficial ownership is dated July 6, 2026, and the filing was published via EDGAR on July 8, 2026.

Candel Therapeutics filed a Form 3 naming Mark E. Sims as chief commercial officer in an initial statement of beneficial ownership dated July 6, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002139479-26-000003), on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here